introduction
The use of complementary and alternative medicine (CAM) has been increasing worldwide [1] [2] [3] over the past two decades, and an estimated 40%-60% of adult cancer patients use CAM [1, [4] [5] [6] [7] . CAM use may improve health-related quality of life (HRQOL) and symptoms that are inadequately managed by conventional medicine [8, 9] .
Substantial evidence from randomized trials among cancer patients supports the use of CAM for symptom control [6] . Acupuncture, for example, has been used with success for post-dissection neck pain [10] and chemotherapy-induced acute nausea severity [11] , as has American ginseng for cancerrelated fatigue [12] . Before CAM methods can be considered part of conventional medicine, however, they must be subjected to greater scientific scrutiny [13] . As 62% of patients in palliative care units (PCUs) expressed an interest in CAM [5] , an investigation of its effects is warranted. Especially, more attention should be paid to the impact of CAM use on HRQOL among the terminally ill patients.
Here, we evaluated whether CAM use influenced outcomes (survival and HRQOL) of cancer patients whose condition had just been judged terminal.
methods study design and recruitment
From July 2005 to October 2006, the Study to Understand Risks, Priority and Issues at End-of-Life (SURPRISE), a multicenter study designed to identify important issues such as use of CAM, quality of life, care burden and needs, end-of-life discussion, advance care planning, and overall satisfaction with care at the end of life, recruited terminal cancer patients for this Korean prospective cohort study from 11 university hospitals and the National Cancer Center. The details of the study design have been published elsewhere [14] . In SURPRISE, patients were eligible to participate if they were aged at least 18 years, diagnosed as terminal at an outpatient or inpatient facility, capable of filling out questionnaires or communicating with an interviewer, and competent enough to understand the intent of the study and provide informed consent. The patients were asked to identify their primary family caregiver, defined as the relative who provided them with the most assistance. The family caregivers were invited to participate in the study but were ineligible if they were not well enough to fill out questionnaires, unable to communicate with an interviewer, or unable to understand the intent of this study well enough to provide informed consent. All participants provided informed consent, and our institutional review boards approved the protocol.
The SURPRISE questionnaires were used to collect demographic data from the patients and the caregivers and clinical information from the patients. The patient and family caregiver questionnaires were similar and took about 20 min to complete. Both the groups were followed for 2 months by mail, and the family caregivers were interviewed by telephone about 3 months after the patient died. The information presented here is based on data collected at baseline, and the QOL data were collected at baseline and again at 1 month.
data collection
Within days of a patient's being diagnosed as terminally ill, SURPRISE collected clinical information using a questionnaire designed to collect information on (i) demographics (age, sex, relationship of caregiver with the patient, level of education, income, and religiousness), (ii) CAM use (type of CAM, satisfaction with CAM used, reason for satisfaction or dissatisfaction), (iii) quality of life, and (4) other end-of-life issues. We administered the questionnaires by face-to-face interviews at an outpatient or inpatient facility to patients and family caregivers at the same time within days of the baseline time point of the study, which was when the physician judged that the cancer was refractory to the conventional anticancer therapy (surgery, radiotherapy, chemotherapy, or hormone therapy) and the patient was likely to die within months. The propensity score is the probability of being a CAM user on the basis of observed characteristics.
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We used the definition of CAM adopted by the US National Center of Complementary and Alternative Medicine (NCCAM): 'CAM is a group of diverse medical and health care systems, practices, and products that are not presently considered to be part of conventional medicine' [15] . NCCAM named five major CAM categories: (i) alternative medical systems (oriental herbal medicine, acupuncture, ayurveda, and homeopathy), (ii) mind-body intervention (yoga, meditation, prayer therapy, music/dance therapy, art therapy, and horticultural therapy), (iii) biologically based therapy (medicinal herbs, vitamin supplements, hydrotherapy, dietary supplements, etc.), (iv) manipulative and body-based therapies, and (v) energy therapies. In this research, we investigated participant's use of all five categories and focused on specific therapies within each category.
All patients completed the European Organization for Research and Treatment of Cancer quality-of-life questionnaire core-30 (EORTC QLQ-C30) instrument. The EORTC QLQ-C30 is composed of five multi-item functional scales that evaluate physical, role, emotional, cognitive, and social function, and one global health status/QOL scale. Three symptom scales measure fatigue, pain, and nausea/vomiting, and six single items assess other symptoms (dyspnea, insomnia, appetite loss, constipation, and diarrhea) and financial difficulties. The Korean-language EORTC QLQ-C30 has been validated [16] .
statistical analysis CAM users were defined as those who reported using at least one form of CAM, and those with questions left unanswered on the questionnaire were defined as nonusers. We summarized the data using descriptive statistics and frequency distributions and examined the association of CAM use with patient demographics, primary cancer site, ECOG (Eastern Cooperative Oncology Group) performance status (PS), and basis of terminal status.
We used propensity scores to minimize bias in the selection of cases versus referents [17] . An individual's propensity score is the probability of being a CAM user on the basis of observed characteristics (sex, age, marital status, educational level, job status, religion, ECOG PS, metastasis, primary cancer site, and reason for terminal status).
We measured survival time from the date of enrollment in the study and used the Kaplan-Meier method to trace survival curves by major CAM categories. We used the Wilcoxon test to estimate the differences in survival for univariate analysis and, for variables that showed statistical significance at the 0.10 level, carried out multivariable analyses using the Cox proportional hazards model to estimate adjusted hazard ratios (aHRs) and 95% confidence intervals (CIs) after adjusting for propensity scores and ECOG PS.
We scored EORTC QLQ-C30 responses according to EORTC scoring manual 3.0 [18] and linearly transformed the data to yield scores from 0 to 100, with a higher functional scores representing better functioning and a high symptom score indicating more severe symptoms. We handled incomplete questionnaires for EORTC QLQ according to the developers' recommendations: if at least half the items in a scale were present, we used their mean as the missing value. We used analysis of covariance to determine significant differences in changes of the HRQOL mean from baseline to 1 month between users of five major categories of CAM and CAM nonusers, adjusting for baseline HRQOL and propensity scores. All statistical tests were two-sided and carried out using SAS version 9.2 (SAS Institute, Inc., Cary, NC). We considered P < 0.05 to be statistically significant, and we defined a 'clinically significant' difference in HRQOL as a 10-point difference in the mean score [18, 19] .
results
Among the study population, 42% used CAM. They had a median age of 58.2 years, compared with 59.0 years for nonusers. Table 1 summarizes the demographic and clinical characteristics for CAM users and nonusers. There was a trend for higher education level to be associated with a higher chance of CAM usage (P = 0.02). After weighting according to propensity scores, the two groups of patients did not differ substantially in any other characteristic ( Table 1) .
The proportion of patients who used CAM among the categories of terminal status was 45.7% among those 'Refractory to chemotherapy', 44.6% among those who registered a 'Refusal of further chemotherapy', and 3.8% among those who reported 'General prostration'.
The most frequently used CAMs were biologically based therapies (84.2%). Mind-body interventions were used with higher frequency (18.3%) than alternative medical systems (12.9%). A few used body-based therapy and energy-based therapy.
We found no difference in overall survival between CAM users and nonusers in univariate analysis and in subgroup analysis of each major CAM category ( Table 2 ). In multivariate analysis adjusting for propensity scores and ECOG PS, CAM users did not have better survival compared with nonusers (aHR, 0.91; 95% CI, 0.74-1.10). Body-based therapy did not show significantly better survival compared with nonusers. (aHR, 0.55; 95% CI, 0.30-1.01) (Figure 1) .
Changes in the adjusted mean of most EORTC QLQ-C30 subscale scores were similar for CAM users and nonusers, except for cognitive functioning and fatigue, where CAM users reported a clinically significant greater worsening of both (Table 3) . Changes in the adjusted mean of most EORTC QLQ-C30 subscale scores did not differ significantly for CAM subcategory users and nonusers. In subgroup analysis by CAM category, users of alternative medical systems reported a clinically significant greater worsening in insomnia subscale (Table 3 ). The use of biologically based and body-based therapies was not associated with worse impairment in any HRQOL subscale ( Table 3) . As only one patient used energy-based therapy, it was not possible to investigate its effect.
discussion
In this large multicenter study, we have described associations between the use of CAM by terminal cancer patients in Korea and their HRQOL and survival. Our finding that 42% of terminal cancer patients used CAM is consistent with the findings of another Korean study [4] [5] [6] [7] and the findings of the population-based palliative care research network (PoPCRN) [20] as well as of studies in Japan [4] [5] [6] [7] , and the USA [6] , despite cultural differences. Our finding that the order of frequency of CAM use was biologically based therapies (especially dietary supplements) > alternative medical systems > mind-body interventions was also consistent with findings from other studies [7, 21] . While patients often use CAM in the hope that it will lead to tumor growth suppression and cure [5, 22] , our study showed that CAM users did not have better survival than nonusers. Moreover, among mind-body interventions, those who prayed showed marginally worse [23, 24] . That CAM therapies have the potential to maintain or to enhance the quality of life [8] , however, has been supported by randomized, controlled trials of acupuncture [10, 11] , and ginseng [12] . The use of mind-body interventions was associated with more clinically significant impairment in global QOL. The use of prayer, for example, was associated with more impairment of QOL changes in global QOL and emotional functioning (data not shown). That finding was consistent with those of a previous study, showing that the use of complementary medicine by cancer patients was associated with severe depression [25] . Such findings suggest the possibility that the use of complementary medicine might not only be a marker of greater psychological distress in this group of patients [25] , but might also cause impairment of QOL. Additionally, the use of biologically based therapies was associated with greater impairment of dyspnea and greater clinically significant impairment of physical functioning and pain. Recent phase I studies with advanced cancer patients also showed that biologically based CAM was associated with poorer overall QOL [2] . Ginseng, in particular, is commonly used by patients with cancer-related fatigue [12] , but it was not associated with any statistically significant benefit in this study (data not shown).
Recently, combining Pan-Asian medicine + vitamins (PAM + V) with the conventional therapy improved survival compared with the conventional therapy alone, suggesting that prospective trials of that combination regimen are justified [26] . Furthermore, acupuncture appears to be a safe and effective treatment for pain [10] , nausea and vomiting [11] , and vasomotor symptoms [27] [28] , and yoga might enhance emotional well-being and serve to buffer QOL deterioration [29] . Therefore, this study, together with the earlier ones, suggests that well-designed clinical trials of CAM in terminally ill patients should be carried out.
Our study had some limitations. First, the nonrandomized study design made it is difficult to draw firm conclusions from the findings. Second, due to the small size sample available for analysis of CAM subcategories, the statistical power might not have been adequate to detect benefits of CAM use. No CAM had a significant effect on HRQOL after the Bonfferoni correction for multiple comparisons with an adjusted α level of 0.003 (α 0 = 0.05/15 = 0.003). Since our multiple comparisons of the effects of CAM on QOL increase the likelihood of a Type 1 error, we defined a 'clinically significant' difference in HRQOL as a 10-point difference in the mean score. Third, it could be argued that the 1-month timeframe was not long enough for changes to become manifest, and a longer study period (3-6 months) is necessary. Additionally, the therapy might be more efficacious among treatable cancer patients than among terminal ones.
While CAM did not provide any definite survival benefit, CAM users reported clinically significant worse HRQOLs. We believe that there is a need for well-designed double-blind randomized clinical trials to evaluate the potential benefits and safety of CAM for terminal cancer patients. 
